BioTheranostics, a leader in molecular diagnostics for cancer, today announced that it has closed a $32 million financing led by MVM Life Science Partners, with participation of Canepa Advanced Healthcare Fund and HealthQuest Capital. As a result of the financing, bioTheranostics will be spun out from bioMérieux, which will remain a minority shareholder, and operate as an independent company.

 Read More